Savara (SVRA) Payables (2010 - 2026)
Savara (SVRA) reported Payables of $4.5 million for Q1 2026, down 19.09% year-over-year from $5.6 million in Q1 2025, and down 21.9% on a QoQ basis from $5.8 million in Q4 2025.
Savara (SVRA) has 17 years of Payables data on file, last reported at $4.5 million in Q1 2026.
- Quarterly Payables fell 19.09% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 19.09% YoY) and the FY2025 annual result came in at $5.8 million, up 26.67% from the prior year.
- Payables fell to $4.5 million in Q1 2026 per SVRA's latest filing, from $5.8 million in the prior quarter.
- Across five years, Payables topped out at $5.8 million in Q4 2025 and bottomed at $805000.0 in Q2 2022.
- The 5-year median for Payables is $3.4 million (2024), against an average of $3.2 million.
- The widest annual swing landed in 2022, when Payables sank 62.45%; it then soared 260.47% in 2023.
- Tracing SVRA's Payables over 5 years: stood at $1.3 million in 2022, then jumped by 162.67% to $3.5 million in 2023, then rose by 29.71% to $4.5 million in 2024, then advanced by 26.67% to $5.8 million in 2025, then declined by 21.9% to $4.5 million in 2026.
- Per Business Quant, the three latest SVRA Payables figures stand at $4.5 million (Q1 2026), $5.8 million (Q4 2025), and $4.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 4.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 5.76 Mn |
| Sep 30, 2025 | 4.14 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 5.56 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 4.61 Mn |
| Jun 30, 2024 | 3.39 Mn |
| Mar 31, 2024 | 2.85 Mn |
| Dec 31, 2023 | 3.50 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | 893,000.00 |
| Jun 30, 2022 | 805,000.00 |
| Mar 31, 2022 | 1.30 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Sep 30, 2021 | 1.28 Mn |
| Jun 30, 2021 | 2.14 Mn |
| Mar 31, 2021 | 2.72 Mn |
| Dec 31, 2020 | 2.60 Mn |
| Sep 30, 2020 | 1.75 Mn |
| Jun 30, 2020 | 2.01 Mn |
| Mar 31, 2020 | 1.23 Mn |
| Dec 31, 2019 | 3.41 Mn |
| Sep 30, 2019 | 2.90 Mn |
| Jun 30, 2019 | 4.44 Mn |
| Mar 31, 2019 | 3.50 Mn |
| Dec 31, 2018 | 3.88 Mn |
| Sep 30, 2018 | 3.24 Mn |
| Jun 30, 2018 | 2.52 Mn |
| Mar 31, 2018 | 3.42 Mn |
| Dec 31, 2017 | 2.78 Mn |
| Sep 30, 2017 | 1.67 Mn |
| Jun 30, 2017 | 1.93 Mn |
| Mar 31, 2017 | 502,000.00 |
| Dec 31, 2016 | 536,000.00 |
| Sep 30, 2016 | 1.50 Mn |
| Jun 30, 2016 | 2.30 Mn |
| Mar 31, 2016 | 2.45 Mn |
| Dec 31, 2015 | 2.60 Mn |
| Sep 30, 2015 | 2.93 Mn |
| Jun 30, 2015 | 2.01 Mn |
| Mar 31, 2015 | 2.28 Mn |
| Dec 31, 2014 | 1.37 Mn |
| Sep 30, 2014 | 1.15 Mn |
| Jun 30, 2014 | 1.23 Mn |
| Mar 31, 2014 | 1.45 Mn |
| Dec 31, 2013 | 964,000.00 |
| Sep 30, 2013 | 794,674.00 |
| Jun 30, 2013 | 950,805.00 |
| Mar 31, 2013 | 575,766.00 |
| Dec 31, 2012 | 698,838.00 |
| Sep 30, 2012 | 343,197.00 |
| Jun 30, 2012 | 468,460.00 |
| Mar 31, 2012 | 316,712.00 |
| Dec 31, 2011 | 451,705.00 |
| Sep 30, 2011 | 489,200.00 |
| Jun 30, 2011 | 872,488.00 |
| Dec 31, 2010 | 479,780.00 |